Skip to main content
. 2014 Feb 12;35(6):1267–1275. doi: 10.1093/carcin/bgu038

Table I.

Characteristics of studies included in the pooled analysis and adjusted HPV prevalence

Study Tissue source Method of HPV detection Histological type HPV types detected
Asia (N = 1312)
    Baba et al. (N = 77) (49) FFPE PCR (SPF10, Inno-LIPA) AC, SCC HPV 6, 16, 18, 33
    Kinoshita et al. (N = 34) (57) FF PCR (TS: HPV 16, 18, 33) AC, SCC, ASqa, LCCa, SmCCa HPV 18
    Iwakawa et al. (N = 275) (53) FF PCR (TS: HPV 16, 18, 33) AC HPV negative
    Hiroshima et al. (N = 49) (52) FFPE PCR (TS: HPV 16, 18, 33) AC, SCC HPV 16
    Goto et al. (N = 296) (51) FFPE PCR GP5+/GP6+ AC, SCC, CSrca HPV 6, 11, 16, 18
    Lim et al, 2009 (N = 99) (56) FFPE ISH (HPV6, 11, 16, 18, 31, 33, 35, 45, 51, 52, 56, 58, 66) AC HPV negative
    Miyagi et al. (N = 176) (8,9) FFPE PCR (TS: HPV 6, 11, 16, 18) AC, SCC HPV 6, 11, 16, 18
    Hirayasu et al. (N = 73) (26) FFPE PCR (TS: HPV 6, 11, 16, 18) SCC HPV 6, 16, 18
    Wang et al. (N = 210) (58) FFPE, Bxb, PEb PCR (MY09/MY11 and TS: HPV 16, 18) AC HPV16, HPV18
    Tsuhako et al. (N = 23) (47) FFPE PCR (TS: HPV 6, 11, 16, 18) ASq HPV 6, 11, 16, 18
    Adjusted HPV 16/18 prevalence (95% CI)c = 4.60% (3.48, 5.73)
    Adjusted HPV 16 prevalence (95% CI)c = 1.49% (0.86, 2.11)
    Adjusted HPV 18 prevalence (95% CI)c = 1.09% (0.66, 1.52)
Europe (N = 1100)
    Syrjanen et al. (N = 131) (14) FFPE ISH (HPV6, 11, 16, 18, 30) SCC HPV 16, Xd
    Syrjanen et al. (N = 77) (55) FFPE PCR (MY09/MY11/GP5+/GP6+) AC, SCC, other HPV 6, 16
    Giuliani et al. (N = 77) (13) FFPE and FF PCR (MY09/MY11/GP5+) AC, SCC, ASqa, LCCa, SmCCa, NSCLCa, othera HPV 6, 16, 18, 31, 53,
    Gorgoulis et al. (N = 68) (11) FFPE and FF PCR (MY09/MY11/GP5+/GP6+) AC, SCC, LCCa HPV negative
    Zaravinos et al. (unpublished results, N = 17) FFPE PCR (GP5+/GP6+) ACe, SCCe, LCCa, NSCLCa HPV negative
    Koshiol et al. (N = 399) (54) FFPE PCR (TS: HPV 16, 18; SPF10 primers (n = 92) AC, SCC, LCC, SmCC, other HPV 16, 18
    Carpagnano et al. (N = 89) (34) FFPE and BBb PCR (consensus HPV primers) AC, SCC, SmCC HPV 16, 30, 31, 39,
    Nuorva et al. (N = 22) (46) FFPE PCR (MY09/MY11) AC HPV 6, 11, 16, 18, 31, 33
    van Boerdonk et al. (N = 220) (59) FFPE PCR (GP5+/GP6+) AC, SCC, LCC, NSCLCe HPV negative
    Adjusted HPV 16/18 prevalence (95% CI)f = 3.03% (2.76, 3.30)
    Adjusted HPV 16 prevalence (95% CI)f = 2.94% (2.68, 3.21)
    Adjusted HPV 18 prevalence (95% CI)f = 0.82%(0.73, 0.92)
South and Central America (N = 105)
    Castillo et al. (N = 36) (50) FFPE PCR (GP5+6+) and SB AC, SCC, SmCCe HPV 16, 18, 33
    Aguayo et al. (N = 69) (48) FFPE PCR (GP5+/GP6+) and SB AC, SCC HPV 6, 16, 18, 31, 45
    Adjusted HPV 16/18 prevalence (95% CI)f= 21.90% (19.61, 24.20)
    Adjusted HPV 16 prevalence (95% CI)f = 19.18% (16.88, 21.49)
    Adjusted HPV 18 prevalence (95% CI)f = 7.78% (6.61, 8.95)
North America (N = 732)
    Taioli et al. (unpublished results, N = 69) FFPE PCR (PGMY09/PGMY11/ GP5+/6+) AC, SCC, LCCa, NSCLCa, othere HPV 51, X
    Pillai et al. (N = 208) (31) FFPE PCR (SPF10, Inno-LIPA) AC, SCC, ASqe, LCC, othere HPV 6, 16, 18, 39, 53, X
    Mehra et al. (N = 62) (32) FFPE PCR (SPF10, Inno-LIPA) AC, SCCe, ASqa, LCCa, HPV 6, 16, 18, 52, 53, 44, 68, 39, 74, 82, X
    Joh et al. (N = 29) (38) FF PCR (GP5+/GP6+) AC, SCCe, LCCa, NSCLCa HPV 11, 16
    Yanagawa et al. (N = 330) (60) FFPE PCR (GP5+/GP6+) and ISH AC, SCC HPV negative
    Bohlmeyer et al. (N = 34) (45) FFPE PCR (MY09/MY11) SCC HPV 18
Adjusted HPV 16/18 prevalence (95% CI)f = 3.78% (3.35, 4.22)
Adjusted HPV 16 prevalence (95% CI)f = 2.03% (1.68, 2.39)
Adjusted HPV 18 prevalence (95% CI)f = 2.49% (2.23, 2.75)

Other: histological type, not otherwise specified. AC, adenocarcinoma; ASq, adenosquamous carcinoma; BB, bronchial brushing; Bx, biopsy tissue; CSrc, carcinosarcoma; FF, fresh frozen; ISH, in situ hybridization; LCC, large cell carcinoma; NSCLC, non-small-cell lung carcinoma, not otherwise specified; PE, pleural effusion; SB, Southern blot; SmCC, small cell carcinoma; TS, type-specific primers.

aNumber of cases ≤6.

bCancer cells present and confirmed by pathologist.

cStudy is included in the model as a random effect.

dType not defined; HPV+ (for the HPV6/11/16/18/30 panel).

eNumber of cases 7–10.

fStudy is included as a covariate in the model.